Company news
Abcellera Biologics Inc. (NASDAQ:ABCL) news
Abcellera Biologics Inc. news releases on 6ix. Latest, Oct 11, 2022: AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022
Press releases — page 3
AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022
October 10, 2022
AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022
October 4, 2022
AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic
September 20, 2022
AbCellera Reports Q2 2022 Business Results
August 8, 2022
AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
August 2, 2022
AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022
July 11, 2022
Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
June 28, 2022
AbCellera Reports Q1 2022 Business Results
May 9, 2022
AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration
May 2, 2022
AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022
April 25, 2022
AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022
April 11, 2022
AbCellera Presents Data on T Cell Engager Platform at AACR 2022
April 7, 2022
AbCellera Reports Full Year 2021 Business Results
February 23, 2022
AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools
February 22, 2022
AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022
February 10, 2022
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
February 10, 2022
AbCellera to Report Full Year 2021 Financial Results on February 24, 2022
January 26, 2022
AbCellera Announces Changes to Its Board of Directors
December 6, 2021
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
December 2, 2021
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer
December 1, 2021
AbCellera Reports Q3 2021 Business Results
November 8, 2021
AbCellera Announces Virtual Presentations at Investor Conferences in November
November 3, 2021
AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021
October 13, 2021
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
September 21, 2021
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
September 20, 2021
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
September 15, 2021
AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
September 14, 2021
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
September 12, 2021
AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference
September 9, 2021
AbCellera Reports Q2 2021 Business Results
August 11, 2021
EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines
August 3, 2021
Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer
August 2, 2021
AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021
July 21, 2021
AbCellera Appoints Neil Berkley as Chief Business Officer
July 12, 2021
AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada
June 21, 2021
AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares
June 9, 2021
CORRECTING and REPLACING AbCellera Reports Q1 2021 Business Results
May 12, 2021
AbCellera to Present Virtually at Berenberg Conference on May 18, 2021
May 10, 2021
AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy
May 5, 2021
New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials
May 3, 2021
AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals
April 28, 2021
AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021
April 20, 2021
AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration
April 13, 2021
AbCellera to Present Virtually at Upcoming Investor Conferences
April 11, 2021
Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19
April 4, 2021
AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
March 31, 2021
AbCellera Reports Full Year 2020 Business Results
March 28, 2021
AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19
March 9, 2021
EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients
March 4, 2021
AbCellera to Present at the SVB Leerink Global Healthcare Conference
February 16, 2021